Gasdermins (GSDMs) genes play complex roles in inflammatory diseases and cancer. Gasdermin-B (GSDMB) is frequently upregulated in human cancers, especially in HER2-amplified breast carcinomas, and can promote diverse pro-tumor functions (invasion, metastasis, therapy-resistance). In particular, the GSDMB shortest translated variant (isoform 2; GSDMB2) increases aggressive behavior in breast cancer cells. Paradoxically, GSDMB can also have tumor suppressor (cell death induction) effects in specific biological contexts. However, whether GSDMB has inherent oncogenic, or tumor suppressor function in vivo has not been demonstrated yet in preclinical mouse models, since mice lack GSDMB orthologue. Therefore, to decipher GSDMB cancer functions in vivo we first generated a novel knock-in mouse model (R26-GB2) ubiquitously expressing human GSDMB2. The comprehensive histopathological analysis of multiple tissues from 75 animals showed that nucleus-cytoplasmic GSDMB2 expression did not clearly affect the overall frequency nor the histology of spontaneous neoplasias (mostly lung carcinomas), but associated with reduced incidence of gastric tumors, compared to wildtype animals. Next, to assess specifically the GSDMB2 roles in breast cancer, we generated two additional double transgenic mouse models, that co-express GSDMB2 with either the HER2/NEU oncogene (R26-GB2/MMTV-NEU mice) or the Polyoma middle-T antigen (R26-GB2/MMTV-PyMT) in breast tumors. Consistent with the pro-tumor effect of GSDMB in HER2+ human breast carcinomas, R26-GB2/MMTV-NEU GSDMB2-positive mice have double breast cancer incidence than wildtype animals. By contrast, in the R26-GB2/MMTV-PyMT model of fast growing and highly metastatic mammary tumors, GSDMB2 expression did not significantly influence cancer development nor metastatic potential. In conclusion, our data prove that GSDMB2 in vivo pro-tumor effect is evidenced only in specific biological contexts (in concert with the HER2 oncogene), while GSDMB2 alone does not have overall intrinsic oncogenic potential in genetically modified mice. Our novel models are useful to identify the precise stimuli and molecular mechanisms governing GSDMB functions in neoplasias and can be the basis for the future development of additional tissue-specific and context-dependent cancer models.

Keywords: Gasdermins, tumorigenesis, Cancer Progression, novel mouse models, pyroptosis
INTRODUCTION

The Gasdermins (GSDMs, named after their Gastric and Dermal expression) are cytosolic proteins of around 50 KDa (Tamura et al., 2007; Saeki and Sasaki, 2012) that have been functionally involved in the genesis and development of cancer (Loveless et al., 2021; Sarrió et al., 2021) and multiple diseases (Broz et al., 2020; Liu et al., 2021). The GSDM family comprises six genes in the human genome (Tamura et al., 2007; Saeki and Sasaki, 2012; de Schutter et al., 2021): GSDMA and GSDMD (which are both located in the 17q21.1 region), GSDMC and GSDML (in 8q24); GSDME/DFNA5 (7p15.3) and DFNB59/PJVK (2q31.2). Mice have ten GSDM genes but GSDMB (also known as GSDML and PRO2521) is the only GSDM member that is not present in the mouse or rat genomes (Tamura et al., 2007). Each GSDM is expressed in diverse tissues in a cell-type specific way (Broz et al., 2020; de Schutter et al., 2021).

The diverse biological functions of GSDM proteins have recently started to emerge. Multiple studies indicate that all family members, except PJVK, can produce a lytic and pro-inflammatory cell death mechanism termed pyroptosis, while specific GSDMs in precise biological contexts can also provoke necrosis, apoptosis, NETosis mitochondrial damage, or autophagy (Broz et al., 2020; Liu et al., 2021). These cell-death promoting functions are normally auto-inhibited through the intramolecular interaction of GSDMs N-terminal (NT, pore-forming) and C-terminal (CT, inhibitory) domains (Ding et al., 2016; Wang and Ruan, 2021). Under certain stimuli and circumstances, the NT is exposed or released, via specific protease cleavage (caspases, granzymes and others) and produces cell death generally through the formation of NT membrane pores (Ding et al., 2016; Wang and Ruan, 2021) and mitochondrial damage (Lin et al., 2015; Shi et al., 2015; de Vasconcelos et al., 2019; Rogers et al., 2019), among other mechanisms. The release of pro-inflammatory molecules during pyroptosis induces robust reaction of the immune system (Broz et al., 2020; Liu et al., 2021). Through their pro-cell death activities and other functions, the GSDMs play a key role in the pathogenesis of several inflammatory or infectious diseases, among others (Broz et al., 2020; Li et al., 2021; Liu et al., 2021). In cancer, the involvement of GSDMs in tumor progression and clinical behavior is intricate, as GSDMs can promote either pro-tumor or anti-tumor effects, depending on the context (Sarrió et al., 2021). On one hand, the activation of GSDM-mediated tumor pyroptosis can lead to immune anti-tumor response, and thus GSDMs can act as tumor suppressor (Wang et al., 2020; Zhang et al., 2020; Zhou et al., 2020; Loveless et al., 2021). On the other hand, GSDM over-expression can mediate pro-tumor effects, and sometimes associate with unfavorable cancer prognosis (Hou et al., 2020; Sarrió et al., 2021). In particular, GSDMB is frequently expressed (mRNA/protein) in esophageal, gastric, colon, liver, breast, cervical and bladder cancers (Carlsson et al., 2015; Shi et al., 2015; de Vasconcelos et al., 2019; Rogers et al., 2019), among other diseases (Broz et al., 2020; Li et al., 2021; Liu et al., 2021). Intriguingly, we demonstrated that GSDMB is a novel therapeutic cancer target, since its overexpression associates with advanced disease or poor prognosis in breast, oral and gastric cancer (Nguyen et al., 2007; Komiyama et al., 2010; Hergueta-Redondo et al., 2014, 2016), and increases invasive and/or metastatic behavior in breast and bladder cancer cells (Hergueta-Redondo et al., 2014; Molina-Crespo et al., 2019; He et al., 2021). Moreover, GSDMB gene is frequently co-amplified with ERBB2/HER2 oncogene in breast and gastro-esophageal carcinomas (Saeki et al., 2009; Hergueta-Redondo et al., 2016), and in HER2+ breast cancers GSDMB upregulation promotes tumor aggressiveness and resistance to anti-HER2 therapies (Hergueta-Redondo et al., 2016). Interestingly, we demonstrated that GSDMB is a novel therapeutic cancer target, since its multiple pro-cancer functions in HER2+/GSDMB + breast cancer cells were reduced in vitro and in vivo by the intracellular delivery of a GSDMB antibody through biocompatible nanocapsules (Molina-Crespo et al., 2019). Altogether, these data indicate that GSDMB could act as an oncogene. However, it could also have antitumor effect in certain biological contexts. Specifically, in cancer cells xenografted in immunocompetent mice, the GSDMB intrinsic pyroptotic function could be activated via immunocyte-derived Granzyme A (GZMA). GZMA cleaves and activates GSDMB NT domain (Chao et al., 2017)): isoform-1 (NM_001042471.1; lacks exon 6, protein of 403 aminoacids–aas– and 45.8 KDa), isoform-2 (NM_018530.2; lacking exons 6 and 7, 394 aas and 45 KDa), isoform-3 (NM_001165958.1; “full-length” protein of 416 aas and 47.4 KDa) and isoform 4 (NM_001042471.1; without exon 7, 407 aas and 46.5 KDa). The differential isoform expression in cells and tissues could lead to distinct functional consequences in normal and pathological contexts, such as inflammatory diseases (Morrison et al., 2013; Panganiban et al., 2018) and cancer (Carl-McGrath et al., 2008; Sun et al., 2008; Hergueta-Redondo et al., 2014; Lutkowska et al., 2017). In this sense, we previously showed that overexpression of either isoform 1 or 2 increases motility and invasion in vitro, but only the isoform 2 (the shortest transcript; hereafter referred to as GSDMB2) promotes tumor growth and metastasis of MCF7 breast cancer xenografts (Hergueta-Redondo et al., 2014). This data suggested an increased pro-tumor potential for GSDMB2.

However, whether GSDMB has inherent oncogenic potential or affect cancer development and progression in vivo has not been tested yet in preclinical mouse models since mice lack GSDMB orthologue. To answer these key questions, in this work we first generated a novel knock-in (KI) mouse model (R26-GB2) ubiquitously expressing human GSDMB2 transcript. Then we created two novel double transgenic mouse models, that co-express GSDMB2 with either the HER2/NEU oncogene (R26-GB2/MMTV-NEU mice) or the Polyoma middle-T antigen (R26-GB2/MMTV-PyMT) in metastatic breast tumors. In these models we performed the first comprehensive in vivo study of GSDMB effects on tumor initiation and development.

MATERIALS AND METHODS

Animals and Ethics Statement

All mouse studies were performed in agreement with the procedures and protocols that have been approved by the internal committees of ethical and animal welfare of the
The commercial mouse strains B6.FVB-Tg (EIIa-Cre) C57BL/6J, FVB/N-Tg (MMTV-PyVT)634Mul/J (Guy et al., 1992a), and FVB/N-Tg (MMTVneu)202Mul/J (Guy et al., 1992b) were purchased from JaxMice. The FVB/NCrI strain was purchased from Charles River. The generation of four novel animal models (R26-STOP-GB2, R26-GB2, R26-GB2/MMTV-PyMT and R26-GB2/MMTV-NEU) is described below.

**Generation of conditional GSDMB2 Knock-in mice (R26-STOP-GB2)**
We generated, in collaboration with the CNIO Transgenic mice Service, mice harboring human GSDMB isoform 2 transcript (NM_018530.2) essentially as previously reported (Nyabi et al., 2009; Martin et al., 2015). Using gene-targeting technology, we
inserted by homologous recombination into the endogenous Rosa26 (R26) locus a construct containing a loxP-flanked PGK-neomycin-STOP cassette (Nyabi et al., 2009) followed by the human GSDMB isoform 2 cDNA (GSDMB2) fused with the HA-tag sequence (Figure 1A). The construct also contains an IRES-sequence followed by GFP gene reporter, which helps in the identification of the Knock-in (KI) animals (Figure 1A).

Expression of the construct is under the control of endogenous Rosa26 promoter, which allows ubiquitous and moderate levels of expression of the transgene (Nyabi et al., 2009). The targeting vector for the homologous recombination was generated by the Gateway cloning DNA technology using the pENTRY plasmid harboring GSDMB2-HA cDNA and the pROSA26-DV vector, as reported previously (Martin et al., 2015). Recombinant clones were sequence-verified using the SIF (5′-ATCATGTCTGGATCCCCATC-3′) and S2R (5′-GGG GCcggaaTTCCGAtATCAAG-3′) primers. The targeting construct was then electroporated into ES cells (C57BL6x129 background; CNIO Transgenic Mice Service), and positive ES clones harboring the construct in the correct orientation were detected by diagnostic PCR (conditions detailed in Supplementary Table S1). Two positive ES clones were used for aggregation with CD1 embryos (CNIO Transgenic mice Service) obtaining 18 male chimeras (all >80% chimerism). After crossing with FVB wildtype (WT) female mice, the correct transmission of the transgene was demonstrated by two PCR tests (Figures 1B,C): a) insertion of the transgene into 3′- and 5′-arm; b) presence of GSDMB-HA transgene and GFP gene. PCR conditions are detailed in Supplementary Table S1; Uncropped PCR gels are provided in Supplementary Figure S1. After confirmation of correct transgene insertion by PCR, we derived one mouse strain of conditional GSDMB2 expression, referred to as R26-STOP-G2. This strain has mixed genetic background (C57BL6x129 from the ES, CD1 from the embryo aggregation and crossed twice with FVB).

**Generation of Knock-in Mice with Ubiquitous Expression of GSDMB2-HA (R26-GB2)**

To analyze in vivo the consequences of ubiquitous GSDMB2 expression in mice, conditional R26-STOP-GB2 male animals were crossed with female mice of the B6.FVB-Tg (EIIa-Cre) C57L6Mmgd/J strain (JAXmice). Adenoviral EIIa promoter expression is restricted to oocytes and preimplantation stages of the embryo, and thus Cre-mediated recombination occurs in a wide range of tissues, including the germ cells that subsequently transmit the genetic modification to progeny. The deletion of the neo-STOP cassette by Cre permits the transcriptional expression, mediated by R26 promoter, of the bicistronic mRNA GSDMB2-HA-IRES-GFP (Figure 1A). To verify the correct excision of the neo cassette and the subsequent activation of the transgenes we designed a diagnostic PCR reaction that preferentially amplifies the excised allele in DNA obtained from tail skin (Figure 1C). PCR conditions are detailed in Supplementary Table S1. Uncropped PCR gels are provided in Supplementary Figure S1. In these mice, GFP light emission, used as a readout of transgene expression, was clearly detected in some fresh tissues, such as tail or testes (Figure 1D) using a Leica MZ10F magnifier. After validation of transgene ubiquitous expression, we crossed heterozygous animals to remove the Cre recombinase and to obtain a line expressing germline GSDMB2-HA-GFP in all tissues. This mouse model, named R26-GB2, with mixed background was crossed two times with the FVB/NCrI strain (Charles River) to ensure that it contained at least 50% FVB genetic background.

**Generation of Breast Cancer Mouse Models Expressing GSDMB2-HA With Either the HER2/NEU Oncogene (R26-GB2/MMTV-NEU) or PyMT Oncogene (R26-GB2/MMTV-PyMT)**

The R26-GB2 model was crossed with either the FVB-MMTV-NEU-202Mul/J or FVB-MMTV-PyMT strains (JaxMice). The mammary glands of female animals from the MMTV-NEU or MMTV-PyMT express the inactivated rat neu oncogene (Guy et al., 1992b) or the Polyoma Middle T antigen (Guy et al., 1992a), respectively, under the regulation of the MMTV (Mouse Mammary Tumor Virus) promoter. Fifty per cent of female MMTV-NEU homozygous mice develop spontaneous invasive breast carcinomas by 7 months of age and metastatic lung colonization occurs in 72% of them after 8 months of age (Guy et al., 1992b). Female MMTV-PyMT mice develop spontaneous invasive breast carcinomas and metastatic lung colonization by 14 weeks of age and (Guy et al., 1992a). To generate R26-GB2/MMTV-NEU or R26-GB2/MMTV-PyMT double transgenic animals, female homozygous R26-GB2 animals were crossed with male homozygous MMTV-NEU or MMTV-PyMT mice. Then, male mice heterozygous for NEU or PyMT and GSDMB2 were crossed with female heterozygous R26-GB2 animals. Genotyping of the NEU and PyMT oncogenes was performed as described in Supplementary Table S1.

**Phenotypic and Histological Characterization of R26-GB2 Model: Study of Spontaneous Tumorigenesis**

Heterozygous R26-GB2 animals were crossed to obtain at least 18 animals from each of the genotypes. A total of 80 mice (42 males, 38 females) corresponding to the three GB2 genotypes (WT, n = 27; GB2+/−, n = 34 and GB2+/+, n = 19) were studied up to 18 months of age. Five animals died spontaneously, and no necropsy could be performed, thus were excluded from the histological analyses. Mice were monitored weekly for the appearance of tumor masses (in any part of the body) or other pathological signs (outcome). Animals were sacrificed when they reached 18 months of age or showed any of the criteria for early termination (scored as 4) (Orellana-Muriana et al., 2012). These criteria include: tumors >15 mm, ulceration or infection of the tumors, body weight loss >20%, enlarged lymph nodes, or extensive skin ulceration, among others (Orellana-Muriana et al., 2012). Animals were euthanized in a CO2 chamber (fill rate of 30% of the chamber volume per minute).
and necropsy was performed immediately. We extracted all organs with macroscopic signs of cancer or other pathologies, as well as other selected organs with normal appearance. Tissues were fixed in 10% formalin and embedded in paraffin blocks. For histologic examination, Hematoxylin-Eosin-stained (H&E) tissue sections were analyzed by two Pathologists (ARS and AT). A total of 328 tissue sections were reviewed (median = 3 organs per mice; minimum 1 and maximum of 14).

Study of Breast Tumorigenesis and Metastatic Potential in R26-GB2/MMTV-NEU or R26-GB2/MMTV-PyMT Mice

Seventy-two R26-GB2/MMTV-NEU female mice, all heterozygous for NEU (21 GB2+/+, 26 GB2+- and 25 WT) were monitored once a week for a mean follow-up time of 15 months. Three GB2+-/ tumor-bearing animals were found dead, and necropsy could not be performed (tumor tissue and lungs were decomposed). Thus, histological data was recorded in 69 mice. In the R26-GB2/MMTV-PyMT model we used 27 PyMT heterozygous female mice (10 GB2+/+ and 17 WT) and breast tumor development was monitored 2–3 times a week until animals reached 15 weeks of age. Animals were euthanized when they either developed a mammary tumor bigger than 1.5 cm long, reached the endpoint date without tumor or showed any of the criteria for early termination (scored as 4) (Orellana-Muriana et al., 2012). Mice were sacrificed by CO2 inhalation (fill rate of 30% of the chamber volume per minute) and all mammary glands with breast tumors were extracted (mean 1.5 tumors/mice in the R26-GB2/MMTV-NEU and 5.6 tumors/mice in the R26-GB2/MMTV-PyMT model), washed in 1x PBS, measured with caliper, and weighted on a scale. The biggest tumor of each mouse was selected, and half of the tissue was quickly frozen in dry-ice and stored at -80°C. We analyzed the cancer incidence, latency (time until detection of palpable tumor), number and weight of tumors. Moreover, to assess metastatic potential the whole lungs were extracted and processed for subsequent paraffin-embedding. Then, whole lungs were serially sectioned into 5 µm-thick tissue sections using a microtome (Leica RM 2255). From these slides, we selected four sections separated by 100 µm in depth and stained with H&E. The rest of the tissue was embedded, no data points were excluded from the analyses. The sample was fixed in 10% formalin and embedded in paraffin blocks. For histologic examination, Hematoxylin-Eosin-stained (H&E) tissue sections were analyzed by two Pathologists (ARS and AT). A total of 328 tissue sections were reviewed (median = 3 organs per mice; minimum 1 and maximum of 14).

Immunohistochemical Analysis

GSDMB2-HA expression was analyzed by immunohistochemistry in 5 µm-thick tissue sections using rat anti-HA (1:200; 3F10, ROCHE) or mouse monoclonal anti-GSDMB [1:10, (Hergueta-Redondo et al., 2016)], following standard methods. HER2/NEU membrane receptor was detected with rabbit anti-HER2 (prediluted; A0485, Dako). Tumor proliferation in the R26-GB2/MMTV-PyMT animals was assessed by PCNA (proliferating cell nuclear antigen) using the MAB424R antibody (1:10,000; clone p10, Millipore). Briefly, after an antigen-retrieval step (Leica Bond ER solution-1, citrate buffer 10 mM pH 5.9–6.1) the primary antibodies were incubated for 1 h at RT, followed by secondary-HRP antibody incubation. The staining was revealed by DAB standard Leica procedure. In negative controls, the primary antibodies were omitted. Immunohistochemical images were taken from representative samples with an Axiophot (Zeiss) microscope coupled with a color DP70 (Olympus camera), using the Olympus DP controller software. For immunofluorescence analysis, secondary goat anti-rat IgG-Alexa 547 (1:1,000, Molecular probes) was incubated for 1 h at RT. Slides were stained with 1:10,000 DAPI (4′,6-diamino-2- fenilindol, Molecular Probes), mounted with Prolong Diamond Antifade Mountant (Molecular Probes) and analyzed by confocal microscopy (LSM710, Zeiss).

Analysis of GSDMB2-HA-GFP Tissue Expression by Western Blot

Six R26-GB2 mice (3 males, 3 females) from each of the GB2 genotypes (WT, GB2+-, GB2+/+) were sacrificed at 20 weeks of age. Sixteen organs were removed, chopped and immediately stored at -20°C. Tumors from 13 R26-GB2/MMTV-NEU and 12 R26-GB2/MMTV-PyMT were also collected. Tissues were homogenized in 50–200 µL lysis buffer (0.1 M NaCl, 0.05 M Tris HCl pH 7.9, 5 µM MgCl2, 5 µM CaCl2, 2% SDS supplemented with 1x protease inhibitor cocktail, ROCHE) by sonication on ice. Lysates were clarified by centrifugation (10,000 rpm, 5 min) and quantified by the BCA method (Pierce). Fifty µg total proteins/per sample were loaded on 10% SDS-PAGE gels. WB were performed by standard methods using rat anti-HA (1:1,000; clone 3F10, ROCHE), rabbit anti-GFP (1:2,000; A6455, Molecular Probes) and mouse anti-GAPDH (1:1,500; 6C5, Calbiochem). As positive control, we used a sample of MCF7 cells expressing GSDMB2-HA (Hergueta-Redondo et al., 2014) and GFP constructs. Uncropped Western blots are provided in Supplementary Figure S1.

Flow Cytometry

To evaluate the proportion of white blood cells from R26-GB2 mice expressing the GSDMB-HA-GFP transgenes we analyzed GFP emission by Flow Cytometry (Cytomics FC 500MPL, Beckman Coulter). Total leukocyte cells, not any specific subpopulation, were analyzed. Peripheral blood from WT and GB2+/+ mice was extracted and processed following the method reported before (Canesin et al., 2015).

Statistical Analyses

Data was obtained from all available animals in the study (each mouse corresponds to a data point) and, unless otherwise specified, no data points were excluded from the analyses. The normal distribution of the continuous data was confirmed by the Kolmogorov–Smirnov test. Statistical analyses were performed using GraphPad 6.0 (GraphPad Software, Inc.) using Chi2 or Fisher’s exact tests to assess differences in categorical variables,
and ANOVA or Student t-test for continuous variables. A p value < 0.05 was considered as statistically significant.

RESULTS

Generation of the Knock-in Mouse Model Ubiquitously Expressing GSDMB2-HA (R26-GB2)

To assess in vivo the cancer roles of GSDMB isoform 2 (GSDMB2), a transcript that promotes invasive and metastatic behavior of MCF7 breast cancer cells (Hergueta-Redondo et al., 2014), we first generated a conditional KI model (R26-STOP-GB2) and then derived the model (R26-GB2) ubiquitously expressing GSDMB2-HA and GFP transgenes in the whole body of the animal (Materials and Methods and Figures 1A–D).

Homozygous (hereafter referred to as GB2+/+) and heterozygous (GB2+/−) R26-GB2 mice are viable and fertile, reproduce normally, and female mice can nurse their litter naturally. In crossings between heterozygous animals, the transgene is transmitted with expected frequencies of the Mendelian inheritance. Transgenic mice do not show evident morphological and developmental alterations or signs of abnormal behavior. GB2+/+ mice tend to have slightly higher body weight, especially in males, than WT animals but the differences do not reach statistical significance (Supplementary Figure S2).

Expression and intracellular Localization of GSDMB2-HA in Tissues

In humans, GSDMB mRNA is detected in multiple organs and tissues, including the digestive tract, respiratory system, immune cells, reproductive organs, and breast tissue among others (Broz et al., 2020). Using immunohistochemistry, GSDMB protein shows different patterns of expression and intracellular localization depending on the tissue and antibody used (Carl-McGrath et al., 2008; Sun et al., 2008; Das et al., 2016; Hergueta-Redondo et al., 2016; Zhou et al., 2020; Protein atlas, https://www.proteinatlas.org/) (Supplementary Table S2). To test GSDMB2 broad expression in our model, first we verified by Western Blot the specific detection of GSDMB2-HA and GFP proteins in 14 organs from male and female GB2 mice (Figure 2A). Expression of the transgenic construct in peripheral blood leukocytes was additionally demonstrated by WB and FACS analysis (Figures 2B, C), where more than 90% of cells showed GFP expression (Figure 2C).

Next, we analyzed GSDMB2-HA expression and subcellular localization in diverse GB2+ and WT tissues by immunohistochemistry using an anti-HA antibody. GSDMB2 showed mainly cytoplasmic localization in some tissues, such as breast, pancreas, or liver, while nucleo-cytoplasmic staining was typically seen in specific tissues/cell types (Figure 3, Supplementary Figure S3; Supplementary Table S2). Nuclear staining was particularly strong in the squamous epithelia of the esophagus, skin epidermis, hair follicles and sebaceous glands, as well as colon epithelia (Figure 3) and testicles (Supplementary Figure S4), among others (Supplementary Table S2). In all tissues, GSDMB2 showed the same staining pattern in heterozygous and homozygous mice, but in GB2+/+ animals nuclear accumulation was more evident. To confirm the nuclear-cytoplasmic localization, additional staining with our anti-GSDMB monoclonal antibody (Hergueta-Redondo et al., 2016) was performed in testis. Both HA and GSDMB antibodies showed the same expression pattern (Supplementary Figure S4A). Moreover, the nuclear localization in this tissue was confirmed further by immuno-fluorescence and confocal microscope analysis (Supplementary Figure S4B). Overall, the nuclear-cytoplasmic pattern of GSDMB2-HA in mice resembles to that observed in the corresponding human tissues (Supplementary Table S2). Furthermore, the differences found in the intracellular localization patterns among tissues could indicate that GSDMB2 has possibly distinct functions depending on the cell context.

Effect of GSDMB2 on Spontaneous Tumorigenesis in vivo

GSDMB over-expression occurs in diverse tumor types and promotes multiple pro-tumor functions in human breast and bladder cancer cells (Sarrió et al., 2021), suggesting that GSDMB could have intrinsic oncogenic properties. To investigate if GSDMB2 expression has in vivo spontaneous tumorigenic activity in any tissue we studied 80 mice for up to 18 months. Mice were monitored weekly for the appearance of tumor masses or other pathological signs and were sacrificed when they showed any of the criteria for early termination specified in Methods or reached 18 months of age. Five mice (all WT) were found dead and necropsy could not be performed, thus post-mortem analyses were done in 75 mice. The overall survival of all the animals (including mice found dead and those sacrificed according to early termination criteria) was similar among GB2+−, GB2+/+ and WT mice (log-rank Mantel Cox test, p = 0.6). At necropsy, tumor formation was investigated in multiple tissues and organs, but macroscopic cancers were only frequently seen in the lungs and stomach (Table 1). In fact, the most common neoplasias observed (41% including all mice) were lung adenocarcinomas, which is consistent with the frequency of these spontaneous tumors in elder mice of the FVB background (Mahler et al., 1996). However, no significant differences in the frequency of lung tumors (Table 1) were observed between WT and GB2 mice (Chi² test p = 0.20, considering the three genotypes; Fisher’s exact test p = 0.79 comparing WT versus the combination of GB2+− and GB2+/+; Fisher’s exact test p = 0.51 comparing WT versus GB2+/+). Moreover, most of these tumors were well-differentiated lung adenocarcinomas, and no differences in histological grade among the genotypes were observed (Supplementary Table S3).

Next, to ensure that GSDMB2-HA protein was expressed in these lung tumors, we performed immunohistochemical analyses using an anti-HA antibody. In GB2+/+ and GB2+/−-lungs we confirmed the diffuse cytoplasmic and focal nuclear staining (stronger in GB2+/+) of GSDMB2-HA in both carcinoma cells
and the normal bronchioles (Figure 4). The positive staining with the C-terminal HA tag proves that the full-length GSDMB2 protein is expressed in tumor cells, but it does not have a clear impact on lung cancer development.

The second most frequent cancer type were gastric tumors. Interestingly, we observed that 17% WT mice (3 male and 1 female) developed macroscopic gastric carcinomas, but none of GB2 mice did (Table 1) (Chi² test p = 0.008, considering the three genotypes; and Fisher’s exact test p = 0.007 comparing WT versus the combination of GB2+/+ and GB2+/−). This result suggests that GSDMB2 might reduce spontaneous gastric tumor formation.

Other types of cancer (e.g., breast cancer) were seldom observed in GB2 or WT animals (Table 1). Therefore, taking all cancers together (irrespective of the tissue of origin) there were no differences in spontaneous tumor frequency among the genotypes (Chi² test p = 0.28, considering the three genotypes; Fisher’s exact test p = 0.33 comparing WT versus the combination of GB2+/+ and GB2+/−).

Since frequent tumors were only seen in lung and stomach, to assess further the effect of GSDMB2 in tumorigenesis, we focused our histological analyses on these organs. Therefore, we evaluated the presence of microscopic tumors or pre-malignant lesions in a series of tissue samples not showing macroscopic evidence of cancer (lung, n = 39; stomach, n = 30; Supplementary Table S4). No tumors were detected in these samples, and the frequencies of premalignant adenomatous lung hyperplasia, gastric adenomas/
polyps, or chronic gastritis, a potential precursor of stomach cancer, were similar in WT and GB2 mice (Supplementary Table S4).

As a whole, these data imply that human GSDMB2 alone does not have a strong overall tumorigenic potential in mice, but it might have instead a potential suppressive effect of gastric carcinogenesis.

**Study of Breast Tumorigenesis and Progression in the R26-GB2/MMTV-NEU and R26-GB2/MMTV-PyMT Models**

While GSDMB over-expression in human breast cancers, specially the HER2 subtype, associates with disease aggressiveness (Hergueta-Redondo et al., 2014, 2016; Molina-Crespo et al., 2019), we only detected one case of spontaneous breast carcinoma in the GB2+/+ mice. This result suggests that the pro-tumor functions of GSDMB observed in human breast cancers may depend on the pre-activation of specific oncogenic stimulus. To test this hypothesis, we evaluated the effect of GSDMB2 expression on breast cancer generation and progression in concert with two different strong oncogenes, HER2/NEU (Guy et al., 1992b) or the PyMT (Guy et al., 1992a). To this end, we generated two double transgenic models, that expresses GSDMB2 ubiquitously (including the breast) with either NEU (R26-GB2/MMTV-NEU model) or PyMT (R26-GB2/MMTV-PyMT mice), which are expressed specifically in the mammary gland. In the R26-GB2/MMTV-NEU model, breast cancer development was monitored for a mean follow-up of 15 months in all experimental groups (WT, 457 days; GB2+/-, 459 days; GB2+/+, 448 days), while in R26-GB2/MMTV-PyMT mice we analyzed cancer development until 15 weeks of age. In both models, strong nucleus-cytoplasmic expression of GSDMB2 was observed in carcinomas cells within the primary tumor and in the lung metastases (Figures 5A,B). Moreover, overall GSDMB2 tumor expression was similar.
in both murine models (Figure 5C). In the context of HER2/NEU-induced tumors, a significant effect of GSDMB2 on breast cancer incidences was noted. In fact, GB2+/− or GB2+/+ mice exhibited double incidence compared to WT controls (Table 2). Moreover, while WT animals developed just one tumor per mouse, GB2+/− or GB2+/+ usually developed multiple tumors (maximum 4, mean 1.67 tumors in GB2+/− or GB2+/+). Since GB2+/− and GB2+/+ showed equal cancer incidence and number of tumors per mice, these mice were analyzed as a single group "GB2+. The cancer latency (time until palpable tumor detection) or the time until tumor reached >1.5 cm (sacrifice) tended to be shorter in WT than GB2+, but differences were not statistically significant (Figure 6). Moreover, no significant variations were observed in the mean tumor weight between groups (Figure 6). At the histological level, all tumors showed high-grade solid invasive pattern, but GB2+ tumors tended to exhibit (while not significant) more frequently areas of glandular/papillary histology than WT ones (Table 2). Regarding metastasis, GB2+ mice and WT showed similar incidence of metastatic tumors (Table 2), whereas the number of metastatic foci was very variable within groups, and thus, no clear effect of the mouse genotype was found (Figure 6).

In the R26-GB2/MMTV-PyMT highly aggressive and fast-growing tumor model, no differences in tumor incidence, cancer latency, or histology were detected between GB2+/+ and WT mice (Table 2). WT and GB2+/+ animals had similar number of tumors (WT mean 5.9 tumors/mouse; GB2+/+ 5.3 tumors), total tumor weight (considering all cancers in each mouse), and cancer proliferation rate (Figure 6). Neither lung cancer incidence (Table 2) nor the metastatic foci number were significantly different between groups (Figure 6).

Therefore, consistent with the pro-cancer effect of GSDMB in human HER2-positive carcinomas (Hergueta-Redondo et al., 2016; Molina-Crespo et al., 2019), the results in murine models show that GSDMB2 promotes tumor incidence specifically in the context of HER2/NEU-driven carcinogenesis. Nonetheless, no strong effect of GSDMB2 on tumor growth, histology and metastatic potential was evidenced in any of the murine models analyzed.

### Analysis of other Histopathological Alterations (non-cancer) in the R26-GB2 model

Finally, apart from cancer, GSDMB function has been implicated in the response to infection with *Shigella enterobacteria* (Hansen et al., 2021) and in the pathobiology of diverse inflammatory diseases, including asthma, inflammatory bowel disease or arthritis, among
others (Li et al., 2012; Morrison et al., 2013; Söderman et al., 2015; Panganiban et al., 2018; Chen et al., 2019; Rana et al., 2022). Therefore, we investigated if R26-GB2 mice exhibited any pathological (non-cancer) phenotype at the microscopic level. Lung pathologies (atelectasis or emphysema) tended to be more frequent in GB2 mice than WT ($p = 0.06$) (Supplementary Table S5). Moreover, our comprehensive analysis of multiple tissues detected infrequent pathological features in other organs but none of them associated significantly with GSDMB2 expression (Supplementary Table S5).

**DISCUSSION**

The GSDMs are functionally linked to multiple human diseases, including infectious, cardiovascular, neurodegenerative pathologies,
chronic inflammatory conditions, deafness syndromes, and cancer, among others (Broz et al., 2020; Li et al., 2021; Liu et al., 2021). In fact, the GSDMs are promising therapeutic targets, with several GSDM-targeted compounds currently under pre-clinical development (Li et al., 2021; Ryder et al., 2021). Nonetheless, to decipher in detail the involvement of GSDMs in human pathologies requires the development of preclinical animal models, since the existence of four GSDM translated isoforms that can play different roles in cancer (Carl-McGrath et al., 2008; Sun et al., 2008; Hergueta-Redondo et al., 2019) shows no spontaneous pathological phenotype (Fuji et al., 2008; Wang et al., 2017; Croes et al., 2019), but GSDM in vivo functions are unveiled only under particular stimuli and biological contexts. For example, Gsmd1, Gsdmd, Gsdme show no spontaneous pathological phenotype (Fujii et al., 2008; Wang et al., 2017; Croes et al., 2019), but GSDM in vivo functions are unveiled only under particular stimuli and biological contexts. Recently, two KI models of GSDMB isoform 1 (Hansen et al., 2021) or isoform 3 (Das et al., 2016) have been reported but, unfortunately, their effect in cancer development was not studied (discussed later). Here, we created the first GSDMB2 KI model, a transcript that increases invasiveness and metastatic potential in human breast cancers (Hergueta-Redondo et al., 2014), and after "whole-body" comprehensive analyses, we proved that GSDMB2 ubiquitous expression neither increases overall tumor development nor significantly affects the aggressiveness of spontaneous generated lung carcinomas. This demonstrates, for the first time, that GSDMB2 alone has no intrinsic tumor initiation capacity in vivo.

Nonetheless, in human breast and gastric cancers, GSDMB over-expression is frequently produced by the co-amplication of GSDMB and HER2/NEU within the 17q12-21 region (Saeki et al., 2009; Hergueta-Redondo et al., 2016), and indeed GSDMB upregulation associates with aggressive behavior, resistance to therapy and poor clinical outcome in HER2-positive breast carcinomas (Hergueta-Redondo et al., 2016; Molina-Crespo et al., 2019). Thus, we next tested if GSDMB2 pro-tumor in vivo functions required the pre-activation of HER2/NEU or other potent oncogenes, like the PyMT. Consistent with the GSDMB pro-tumor functions in human HER2 carcinomas, our two novel breast cancer models (R26-GB2/MMTV-NEU and R26-GB2/MMTV-PyMT) proved that GSDMB2 expression significantly augments breast cancer formation only in the context of HER2-driven tumorigenesis. Analyses by western blot and immunohistochemistry (using an antibody against the C-term HA tag) proved that full-length GSDMB2 was equally expressed in both models, demonstrating that the distinct effect in tumor development was not due to different levels of GSDMB overexpression but the biological context. Moreover, confirming our in vitro and/or in vivo data in human breast cancer cell lines and biopsies (Hergueta-Redondo et al., 2016; Molina-Crespo et al., 2019) GSDMB2 levels did not produce a clear effect on tumor weight or proliferation in our murine models. However, unlike human HER2 breast carcinomas and xenografted MCF7 cells, GSDMB upregulation did not significantly associate with increased metastatic potential. It should be noted that in the murine breast cancer models used, cancer cells only metastasize to the lungs, while in humans, metastatic locations are more diverse.

### Table 2: Cancer incidence, histology, and frequency of metastasis in the R26-GB2/MMTV-NEU and R26-GB2/MMTV-PyMT models.

| Model                      | Genotype       | Incidence | Histology | Metastasis |
|----------------------------|----------------|-----------|-----------|------------|
| R26-GB2/MMTV-NEU model     | WT             | 5/25 (20%)| Solid     | 0/5 (0%)   |
|                            | GB2+/-         | 12/26 (46%)| Solid with necrosis | 2/9 (20%) |
|                            | GB2+/+         | 9/21 (43%)| Solid with glandular/papillary area | 3/9 (30%) |

**Note:** p value based on Fisher’s exact test comparing either WT vs. GB2+/- and +/- combined.

**Table 2:**

| Model                      | Genotype       | Incidence | Histology | Metastasis |
|----------------------------|----------------|-----------|-----------|------------|
| R26-GB2/MMTV-PyMT model    | WT             | 17/17 (100%)| Solid     | 3/17 (18%)  |
|                            | GB2+/-         | 10/10 (100%)| Solid with necrosis | 4/10 (40%) |
|                            | GB2+/+         | ND        | Solid with glandular/papillary area | 4/10 (40%) |

**Note:** p value based on Fisher’s exact test comparing WT vs. GB2+/-.

**Note:** In three GB2+/mice tumor histology could not be performed due to tissue degradation. ND, not done.
Overall, our breast cancer models can help to get novel mechanistic insights of the context-dependent role of GSDMB in cancer, and the R26-GB2/MMTV-NEU mice can be potentially used in the future to test novel oncologic treatments in HER2-positive tumors. Moreover, our results confirm previous studies in other GSDMs highlighting the relevance of the experimental setting to unveil the diverse, and sometimes opposing, roles of GSDM in tumors. For instance, human GSDME, broadly considered as tumor suppressor gene, reduces xenograft tumor growth in immunocompetent but not in immunodeficient mice (Rogers et al., 2019; Zhang et al., 2020). Additionally, Gsdme KO mice exhibit no clear effects on carcinogenesis, tumor differentiation and progression in two experimental models of intestinal cancer (the chemical

![FIGURE 6](Frontiers in Cell and Developmental Biology | www.frontiersin.org February 2022 | Volume 10 | Article 813929)

| A | Cancer Latency | Time until tumor >1.5cm |
|---|---|---|
| | WT (n=5) GB2+ (n=21) | WT (n=5) GB2+ (n=21) |
| | p=0.26 | p=0.19 |

| A | Total tumor weight | Number of Metastatic foci |
|---|---|---|
| | WT (n=5) GB2+ (n=17) | WT (n=3) GB2+ (n=14) |
| | p=0.37 | p=0.69 |

| B | Cancer Latency | Proliferation rate (PCNA staining) |
|---|---|---|
| | WT (n=17) GB2+/+ (n=10) | WT (n=17) GB2+/+ (n=10) |
| | p=0.97 | p=0.85 |

| B | Total tumor weight | Number of Metastatic foci |
|---|---|---|
| | WT (n=17) GB2+/+ (n=10) | WT (n=13) GB2+/+ (n=5) |
| | p=0.19 | p=0.66 |

**FIGURE 6** Effect of GSDMB2 on breast cancer generation and cancer progression in the R26-GB2/MMTV-NEU and R26-GB2/MMTV-PyMT mouse models. **(A)** Comparisons between GB2+ (GB2+/+ and GB2+/− combined) and WT mice of the GB2/MMTV-NEU model (median age 15 months). All mice were heterozygous for HER2/NEU oncogene. **(B)** Comparisons between GB2+/+ and WT mice of the GB2/MMTV-PyMT model (15 weeks of age). All mice were heterozygous for PyMT oncogene. Tumor latency: time until detection of palpable mammary tumors. Total tumor weight: Each data point represents the added weight of all tumors for each mouse. Proliferation rate: Percentage of PCNA-positive staining (only the biggest tumor of each mouse). Lung metastasis foci: number of metastatic lesions (only animals with metastasis). Graphs show all data points, mean values (line) and standard deviations (error bars). Statistical differences were tested by Student’s t-test.
induction by azoxymethane -AOM- or crossing with the 
Apc1638N/+ intestinal cancer mouse strain) (Croes et al.,
2019), but these animals have significantly reduced colitis severity and tumor formation when AOM was combined with 
Dextran Sodium Sulphate (Tan et al., 2020).

Likewise, contrary to its pro-tumor effects, GSDMB can have tumor suppressor function in certain conditions (Zhou et al.,
2020). Specifically, while exogenous GSDMB over-expression into 
two aggressive murine cancer xenografts models did not affect tumor progression, the treatment with PD-1 immune checkpoint inhibitors activated the GSDMB intrinsic pyroptotic activity in 
tumor cells through a non-cell autonomous mechanism mediated 
by NK and CD4+ T cells (Zhou et al., 2020). Only upon immune 
activation, mouse immunocytes released GZMA that cleaved 
human GSDMB, thus indicating that triggering an endogenous tumor reduction in vivo via GSDMB-mediated pyroptosis is not spontaneous and requires additional signals. Remarkably, 
consistent with GSDMB tumor suppressor function, Zhou and 
colleagues report a frequent GSDMB downregulation in 
gastroesophageal carcinomas, which contradicts previous studies in these tumors (Saeki et al., 2009, 2015; Komiyama et al., 2010).

In this sense, we observed that four (17%) WT animals and no 
GB2 mice of the R26-GB2 model developed macroscopic gastric 
carcinomas, while no differences in premalignant gastric lesions 
were observed between the genotypes. Unfortunately, the 
mechanism by which GSDMB2 might reduce gastric carcinomas could not be explored in our mice as we did not obtain any GSDMB2-positive gastric cancer. A potential 
GSDMB-mediated immune rejection of gastric tumor cells, as 
described above, is unlikely in our model since GSDMB2 is 
expressed in diverse cell types, including the immunocytes. In 
fact, it is possible that the immune recognition and stimulation of the anti-tumor response may be difficult to achieve in transgenic animals where the tumor and the surrounding cells carry the same genetic modifications, like our models and the Gsdme KO mice (Croes et al., 2019).

Moreover, the implication of GSDMB in gastric carcinogenesis is intricate, since normal and neoplastic cells differ in the usage of the 
two GSDMB gene promoters (LTR-derived and cellular 
promoter). This can lead to differential expression of GSDMB isoforms and total protein levels between healthy and cancerous 
stomach tissue (Sin et al., 2006; Komiyama et al., 2010).

Therefore, to evaluate further the functional role of GSDMB 
in gastric cancer requires future studies expressing each of the 
isoforms under the recently described stomach-specific gene 
promoters (Seiditz et al., 2019). Besides, it would be also 
necessary crossing the distinct GSDMB mice with GEMMs that 
develop gastric carcinomas (Jiang and Yu, 2017).

In addition to the effect of GSDMB on cancer, our study offers 
other interesting results. We demonstrated that GSDMB2 exhibits differential nuclear and/or cytoplasmic staining 
patterns among healthy tissues/organs, that mostly resemble 
those in the corresponding human tissues (Carl-McGrath et al., 2008; Sun et al., 2008; Das et al., 2016; Hergueta-
Redondo et al., 2016; Zhou et al., 2020). Moreover, in 
spontaneous lung carcinomas (R26-GB2) and oncogene-driven 
breast cancers, GSDMB2 was mostly cytoplasmic but nuclear 
localization was noted in some tumor areas (usually more intense 
in GB2+/+ than GB2+/-mice, indicating enhanced protein 
accumulation with increased GSDMB2 gene dosage). All these 
data suggest that this protein may have distinct biological functions depending on the cellular context and intracellular localization. GSDMB possesses a putative nuclear localization signal (residues 242–261) that is present in all GSDMB isoforms, 
and mutation/deletion of this sequence excludes GSDMB from 
the nucleus (Sun et al., 2008; Das et al., 2016). To date, the 
mechanism of GSDMB nucleus-cytoplasm shuttling is unknown, 
but nuclear GSDMB can regulate gene transcription. Indeed, 
nuclear GSDMB provokes the transcriptional induction of the 
same set of genes (TGF-β1 and 5-lipoxygenase) in human bronchial epithelial cells and the lungs of the hGSDMB261-Cre 
KI model (ubiquitously expressing the longest isoform, 
GSDMB3) after asthma challenge (Das et al., 2016).

Transcriptional regulation by GSDMB3 provoked an asthmatic phenotype associated with increased airway hyper-
responsiveness and remodeling in GEMMs (Das et al., 2016).

In this sense, our R26-GB2 model can be useful in future studies to assess whether GSDMB regulates specific genes in particular tissues/cell types from both healthy and cancer conditions.

In addition to gene regulation, and despite physiological differences between humans and mice, accumulating evidences prove that exogenous human GSDMB expressed (mostly in the 
cytosol) in mouse cells can interact with mouse proteins and 
maintain other important biological activities. For instance, the 
mouse proteases caspase-4 and granzyme A, two key regulators/ 
effectors of GSDMB, produce similar biological effect on GSDMB 
than the corresponding human proteases (Chen et al., 2019; Zhou et al., 2020).

Therefore, based on the above evidences proving the preclinical validity of GSDMB mouse models, and the overall 
similarity in GSDMB expression patterns between human and mouse tissues observed in our R26-GB2 mice, we propose that 
this strain could be also useful for deciphering the implication of 
GSDMB in other diseases, such as response to pathogens (Hansen et al., 2021), and inflammatory pathologies (asthma, type-I diabetes, inflammatory bowel diseases, biliary cirrhosis, and rheumatoid arthritis) (Li et al., 2012; Morrison et al., 2013; Söderman et al., 2015; Panganiban et al., 2018; Chen et al.,
2019; Rana et al., 2022). In fact, using GEMM models, only 
the mechanistic implication of GSDMB3 has been demonstrated 
in asthma, while the GSDMB bactericidal function was not 
validated in GSDMB1 KI mice (Hansen et al., 2021). Strikingly, the asthmatic phenotype of the hGSDMB261-Cre 
model was mechanistically mediated by the transcriptional regulation of certain genes (Das et al., 2016), not via a cell 
death mechanism, while in human lung cells asthma has been 
linked to the pyroptotic effect of specific GSDMB isoforms 
(Morrison et al., 2013; Das et al., 2016; Panganiban et al.,
2018). This suggests different pathogenic effects of GSDMB 
variants in asthma. While we did not evaluate the presence of 
asthmatic phenotype in our R26-GB2 model, we observed that 
other lung pathologies (atelectasis and emphysema) were more 
frequent (p = 0.06) in GB2 mice.
Summarizing, future studies comparing the different GSDMB isoform GEMMs would be required to identify the precise functions of each GSDMB variant in cancer and other diseases.

CONCLUSIONS
The phenotypic characterization of our three novel GEMMs proves that GSDMB2 pro-tumor function is dependent on the biological context: GSDMB2 alone does not have strong in vivo spontaneous oncogenic properties (though a potential reduction of gastric tumorigenesis requires future studies), while in the mammary gland, it fuels carcinogenesis in concert with the HER2, and not PyMT, oncogene. Our GEMMs not only validate in vivo the role of GSDMB in human HER2-positive breast cancer but can also be useful for the future development of other tissue-specific and context-dependent disease models.

DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT
The animal study was reviewed and approved by the internal committees of ethical and animal welfare of the Institutions (Universidad Autonoma de Madrid and Instituto de Investigaciones Biomedicas Alberto Sols-CSIC) and the local authorities (Comunidad de Madrid, PROEX424/15 and PROEX 235,6/20).

AUTHOR CONTRIBUTIONS
DS conceived and designed the study, contributed to the generation and characterization of the mouse models, performed the experiments, generated and analyzed the data and wrote the manuscript. AR-S and AT performed the experiments, generated and analyzed the data, contribution analysis or writing the manuscript. All the authors read and approved the final manuscript.

REFERENCES
Broz, P., Pelegrín, P., and Shao, F. (2020). The Gasdermins, a Protein Family Executing Cell Death and Inflammation. Nat. Rev. Immunol. 20, 143–157. doi:10.1038/s41577-019-0228-2
Canesin, G., Cuevas, E. P., Santos, V., López-Menéndez, C., Moreno-Bueno, G., Huang, Y., et al. (2015). Lysyl Oxidase-like 2 (LOXL2) and E47 EMT Factor: Novel Partners in E-Cadherin Repression and Early Metastasis Colonization. Oncogene 34, 951–964. doi:10.1038/onc.2014.23
Carl-McGrath, S., Schneider-Stock, R., Ebert, M., and Röcken, C. (2008). Differential Expression and Localisation of Gasdermin-like (GSDML), a Novel Member of the Cancer-Associated GSDMDC Protein Family, in Neoplastic and Non-neoplastic Gastric, Hepatic, and colon Tissues. Pathology 40, 13–24. doi:10.1080/00313020701716250
Chao, K. L., Kulakova, L., and Herzberg, O. (2017). Gene Polymorphism Linked to Increased Asthma and IBD Risk Alters Gasdermin-B Structure, a Sulfatide and Phosphoinositide Binding Protein. Proc. Natl. Acad. Sci. USA 114, E1128–E1137. doi:10.1073/pnas.1616783114
Chen, Q., Shi, P., Wang, Y., Zou, D., Wu, X., Wang, D., et al. (2019). GSDMB Promotes Non-canonical Pyroptosis by Enhancing Caspase-4 Activity. J. Mol. Cel Biol. 11, 496–508. doi:10.1093/jmcb/mjy056
Croes, L., Fransen, E., Hylebos, M., Buys, K., Hermans, C., Broeckaerts, G., et al. (2019). Determination of the Potential Tumor-Suppressive Effects of Gsdme in a Chemically Induced and in a Genetically Modified Intestinal Cancer Mouse Model. Cancers 11, 1214. doi:10.3390/cancers11081214
Das, S., Miller, M., Beppu, A. K., Mueller, J., McGough, M. D., Vuong, C., et al. (2016). GSDMB Induces an Asthma Phenotype Characterized by Increased Airway Responsiveness and Remodeling without Lung Inflammation. Proc. Natl. Acad. Sci. USA 113, 13132–13137. doi:10.1073/pnas.1610433113
de Schutter, E., Roelandt, R., Riquet, F. B., van Camp, G., Wullaert, A., and Vandenberghe, P. (2021). Punching Holes in Cellular Membranes: Biology and Evolution of Gasdermins. Trends Cell Biol. 31, 500–513. doi:10.1016/j.tcb.2021.03.004

de Vasconcelos, N. M., van Opdenbosch, N., van Gorp, H., Parthoens, E., and Lamkanfi, M. (2019). Single-cell Analysis of Pyroptosis Dynamics Reveals Conserved GSDMD-Mediated Subcellular Events that Precede Plasma Membrane Rupture. Cell Death Differ 26, 146–161. doi:10.1038/s41418-018-0106-7

Ding, J., Wang, K., Liu, W., She, Y., Sun, Q., Shi, J., et al. (2016). Pore-forming Activity and Structural Autoinhibition of the Gasdermin Family. Nature 535, 111–116. doi:10.1038/nature18590

Fujii, T., Tamura, M., Tanaka, S., Kato, Y., Yamamoto, H., Mizushima, Y., et al. (2008). Gasdermin D (Gsdmd) Is Dispensable for Mouse Intestinal Epithelium Development. Genesis 46, 418–423. doi:10.1002/dvg.20412

Guy, C. T., Cardiff, R. D., and Muller, W. J. (1992a). Induction of Mammary Tumors by Expression of Polyomavirus Middle T Oncogene: A Transgenic Mouse Model for Metastatic Disease. Mol. Cell. Biol. 12, 954–961. doi:10.1128/mbc.12.3.954-961.1992

Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. (1992b). Expression of the Neu Protooncogene in the Mammary Epithelium of Transgenic Mice Induces Metastatic Disease. Proc. Natl. Acad. Sci. 89, 10578–10582. doi:10.1073/pnas.89.22.10578

Hansen, J. M., de Jong, M. F., Wu, Q., Zhang, L.-S., Heider, D. B., Alto, L. T., et al. (2021). Pathogen-Induced Ubiquitination of GSDMB Inhibits NK Cell Bactericidal Functions. Cell 184, 3178–3191. doi:10.1016/j.cell.2021.04.036

He, H., Yi, L., Zhang, B., Yan, B., Xiao, M., Ren, J., et al. (2021). USP24-GSDMB Complex Promotes Bladder Cancer Proliferation via Activation of the STAT3 Pathway. Int. J. Biol. Sci. 17, 2417–2429. doi:10.7150/ijbs.54442

Herugue-Rodrino, M., Sarrió, D., Molina-Crespo, Á., Megías, D., Mota, A., Rojo-Clavijo, F. B., van Camp, G., Wullaert, A., and Vandenberghe, P. (2012). Genome-wide Association Studies of Asthma Indicate Opposite Immunopathogenesis Direction from Autoimmune Diseases. J. Allergy Clin. Immunol. 130, 861. doi:10.1016/j.jaci.2012.04.036

Jagodziński, A., Sotiri, E., and Sarrió, D. (2019). Gasdermin-B Novel Cancer Mouse Models. Mol. Diagn. Ther. 21, 199–207. doi:10.1007/s40291-017-0236-1

Muller, J. F., Stokes, W., Mann, P. C., Takaoka, M., and Maronpot, R. R. (1996). Spontaneous Lesions in Aging FVB/N Mice. Toxicol. Pathol. 24, 710–716. doi:10.1080/0192673960260606

Martin, A., Salvador, F., Moreno-Bueno, G., Floristán, A., Ruiz-Herguido, C., Cuevas, E. P., et al. (2015). Lysyl Oxidase-like 2 Represses Notch1 Expression in the Skin to Promote Squamous Cell Carcinoma Progression. EMBO J. 34, 1090–1109. doi:10.15252/embj.201489975

Molina-Crespo, Á., Cadete, A., Sarrió, D., Gámez-Chiachio, M., Martínez, L., Chao, K., et al. (2019). Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces Her2 Breast Cancer Aggressiveness. Clin. Cancer Res. 25, 4846–4858. doi:10.1158/1078-0432.CCR-18-2381

Morrison, F. S., Locke, J. M., Wood, A. R., Tuke, M., Pasko, D., Murray, A., et al. (2013). The Splice Site Variant Rs11078928 May Be Associated with a Genotype-dependent Alteration in Expression of GSDMB Transcripts. BMC Genomics 14, 627. doi:10.1186/1471-2164-14-627

Nguyen, S. T., Hasegawa, S., Tsuda, H., Tomioka, H., Ushijima, M., Noda, M., et al. (2007). Identification of a Predictive Gene Expression Signature of Cervical Lymph Node Metastasis in Oral Squamous Cell Carcinoma. Cancer Sci. 98, 740–746. doi:10.1111/j.1349-7006.2007.00454.x

Nyabi, O., Naessens, M., Haigh, K., Gembarska, A., Goossens, S., Maetens, M., et al. (2009). Efficient Mouse Transgenesis Using Gateway-Compatible ROSA26 Loxp-containing Vectors and Fl Hybrid ES Cells. Nucleic Acids Res. 37, e55. doi:10.1093/nar/gkp112

Orellana-Muriana, J. M., NeurmethodsMartínez Murillo, R., and Martínez-Alarcón, L. (2012). “ in Animal Models Of Brain Tumors. Totowa: Humana Press, 21–36. doi:10.1007/978-509-2012_59 Animal Models in Cancer Research: Assessment of Severity and the Application of Humane Endpoints

Panganiban, R. A., Sun, M., Dahlín, A., Park, H.-R., Kan, M., Himes, B. E., et al. (2018). A Functional Splice Variant Associated with Decreased Asthma Risk Abolishes the Ability of Gasdermin B to Induce Epithelial Cell Pyroptosis. J. Allergy Clin. Immunol. 142, 1469–1478. doi:10.1016/j.jaci.2017.11.040

Rana, N., Privitera, G., Kondolf, H. C., Bulek, K., Lechuga, S., De Salvo, C., et al. (2022). GSDMB Is Increased in IBD and Regulates Epithelial Restitution/repair Independent of Pyroptosis. Cell 185 (21), 283–298. doi:10.1016/j.cell.2021.12.024

Rogers, C., Erkes, D. A., Nardone, A., Aplin, A. E., Fernandes-Alnemri, T., and Alnemri, E. S. (2019). Gasdermin Pores Permeabilize Mitochondria to Augment Caspase-3 Activation during Apoptosis and Inflammasome Activation. Nat. Commun. 10, 1689. doi:10.1038/s41467-019-09397-2

Ryder, C. B., Kondolf, H. C., O’Keefe, M. E., Zhuo, B., and Abbott, D. W. (2021). Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential. J. Mol. Biol. 167183. doi:10.23736/S0022-2308.21.167183

Saeki, N., Komatsu, R., Chiwaki, F., Yanagihara, K., and Sasaki, H. (2015). A GSDMB Enhancer-Driven HSV Thymidine Kinase-Expressing Vector for Controlling Occult Peritoneal Dissemination of Gastric Cancer Cells. BMC Cancer 15, 1. doi:10.1186/s12885-015-1436-1

Saeki, N., and Sasaki, H. (2012). “‘Gasdermin Superfamily: A Novel Gene Family Functioning in Epithelial Cells,” in Endothelium And Epithelium. Editors J. Carrasco and M. Mota (Hauppauge, New York: Nova Science Publishers, Inc.), 193–211.

Saeki, N., Utsui, T., Aoyagi, K., Kim, D. H., Sato, M., Mabuchi, T., et al. (2009). Distinctive Expression and Function of FourGSDMAMammalian Genes (GSDMA-D) in normal and Malignant Upper Gastrointestinal Epithelium. Genes Chromosomes Cancer. 48, 261–271. doi:10.1002/gcc.20636

Sarrió, D., Martinez-Val, J., Molina-Crespo, Á., Sánchez, L., and Moreno-Bueno, G. (2021). The Multifaceted Roles of Gasdermins in Cancer Biology and Oncologic Therapies. Biochim. Biophys. Acta (BBA) - Rev. Cancer 1876, 188635. doi:10.1016/j.bbcan.2021.188635

Shi, P., Tang, A., Xian, L., Hou, S., Zou, D., Lv, Y., et al. (2015). Loss of Conserved Gsdma3 Self-Regulation Causes Autohpy and Cell Death. Biochem. J. 468, 325–336. doi:10.1042/BJ20150204
Sin, H.-S., Huh, J.-W., Kim, D.-S., Kang, D. W., Min, D. S., Kim, T.-H., et al. (2006). Transcriptional Control of the HERV-H LTR Element of the GSDML Gene in Human Tissues and Cancer Cells. *Arch. Virol.* 151, 1985–1994. doi:10.1007/s00705-006-0764-5

Söderman, J., Berglind, L., and Alner, S. (2015). Gene Expression-Genotype Analysis Implicates GSDMA, GSDMB, and LRRC3Cas Contributors to Inflammatory Bowel Disease Susceptibility. *Biomed. Res. Int.* 2015, 1–10. doi:10.1155/2015/834805

Sun, Q., Yang, J., Xing, G., Sun, Q., Zhang, L., and He, F. (2008). Expression of GSDML Associates with Tumor Progression in Uterine Cervix Cancer. *Translational Oncol.* 1, 73–1IN1. doi:10.1593/tlo.08112

Tamura, M., Tanaka, S., Fujii, T., Aoki, A., Komiyama, H., Ezawa, K., et al. (2007). Members of a Novel Gene Family, Gsdm, Are Expressed Exclusively in the Epithelium of the Skin and Gastrointestinal Tract in a Highly Tissue-specific Manner. *Genomics* 89, 618–629. doi:10.1016/j.ygeno.2007.01.003

Tan, G., Huang, C., Chen, J., and Zhi, F. (2020). HMGBl Released from GSDME-Mediated Pyroptotic Epithelial Cells Participates in the Tumorigenesis of Colitis-Associated Colorectal Cancer through the ERK1/2 Pathway. *J. Hematol. Oncol.* 13, 149. doi:10.1186/s13045-020-00985-0

Wang, C., and Ruan, J. (2021). Mechanistic Insights into Gasdermin Pore Formation and Regulation in Pyroptosis. *J. Mol. Biol.*, 167297. doi:10.1016/j.jmb.2021.167297

Wang, Q., Wang, Y., Ding, J., Wang, C., Zhou, X., Gao, W., et al. (2020). A Bioorthogonal System Reveals Antitumour Immune Function of Pyroptosis. *Nature* 579, 421–426. doi:10.1038/s41586-020-2079-1

Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., et al. (2017). Chemotherapy Drugs Induce Pyroptosis through Caspase-3 Cleavage of a Gasdermin. *Nature* 547, 99–103. doi:10.1038/nature22393

Zhang, Z., Zhang, Y., Xia, S., Kong, Q., Li, S., Liu, X., et al. (2020). Gasdermin E Suppresses Tumour Growth by Activating Anti-tumour Immunity. *Nature* 579, 415–420. doi:10.1038/s41586-020-2071-9

Zhou, Z., He, H., Wang, K., Shi, X., Wang, Y., Su, Y., et al. (2020). Granzyme A from Cytotoxic Lymphocytes Cleaves GSDMB to Trigger Pyroptosis in Target Cells. *Science* 368, eaaz7548. doi:10.1126/science.aaz7548

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Sarrio, Rojo-Sebastián, Teijo, Pérez-López, Díaz-Martín, Martínez, Morales, García-Sanz, Palacios and Moreno-Bueno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.